Excellent find Temsamany!

Company press release from Don? ?  Shhhhhhhush!  Our Chief Sabotage Officer is tryin to keep everythin on the down low.

Here are some interesting clips from the study.  Comments welcome on the part I have highlighted.

Apabetalone inhibits kidney damage in diabetes

In our previous research, it was demonstrated that the inhibition of NLRP3 or caspase-1 suppressed NLRP3 inflammasome activation. Due to this treatment, there was a decrease in renal fibrosis, a reduction in the expression of inflammatory factors, and an improvement in proteinuria and renal function. 

Therefore, intervention of NLRP3 inflammasome seems encouraging as a possible therapeutic strategy for DKD.

Research has shown that apabetalone decreases the likelihood of significant negative cardiovascular incidents and hospitalization due to heart failure in a specific subset of individuals with CKD 

[22]

Apabetalone was found to restore postischemic levels of angiogenesis and limb perfusion in diabetic mice by inhibiting platelet-responsive protein-1 transcription 

[12]

. Following a 24-hour exposure to 25 μM apabetalone, monocytes from individuals with type 2 diabetes and cardiovascular disease (CVD) exhibited reduced levels of inflammatory indicators 

[21].

Apabetalone inhibits cell pyroptosis in db/db mice

Our study is pinpoint BRD4's function in inflammation as well as pyroptosis, both of which are essential for the development and course of DKD. Discovering the high levels of acetylated H3K27 on the PLK1 promoter enabled us to validate the essential role of BRD4 in activating PLK1 transcription. This epigenetic modification, which relies on P300 for transduction, leads to the induction of NLRP3-mediated pyroptosis, inflammation, and fibrosis, ultimately hastening the progression of DKD. Furthermore, our results clearly demonstrated that apabetalone serves as a safeguard against this mechanism by suppressing the expression of BRD4.

Since apabetalone has already undergone testing in multiple clinical studies and received FDA approval, more preclinical research and exploratory trials with DKD patients are made possible by our findings. The results from the study of mechanisms, along with the data obtained from clinical trials, provide support for the continued advancement of apabetalone as a potential treatment for DKD.

https://www.sciencedirect.com/science/article/pii/S1043661824002512

Not sure how a source like Science Direct might misunderstand the FDA status of Apabetalone...
I guess they have never met someone like Don who can blow a multi-billion dollar FDA Breakthrough Thereapy Designation opportunity.  They can't conceive how the FDA BTD hasn't been converted into a blockbuster treatment by now...